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An immunoaffinity chromatography extraction capillary liquid chromatography separation has been
coupled to electrospray ionization mass spectrometry for on-line characterization of drug metabolites of a
therapeutic peptide in plasma. It is demonstrated that the selectivity, sensitivity and molecular weight data
provided by immunoaffinity chromatography coupled to liquid chromatography/mass spectrometry
provides a means of rapidly achieving qualitative determinations of small amounts of material in
complicated biological matrices such as plasma. The ability to detect the peptide in rat plasma at a level of
10 ng/mL is demonstrated using this method. In addition, experiments to study the epitope of the peptide by
enzymatic digestion and mass spectrometry are also discussed. The method is proposed as an alternative
approach to studying the metabolism of therapeutic peptides. Copyright# 2000 John Wiley & Sons, Ltd.
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It has become increasingly important to elucidate and
understand the metabolism of therapeutic peptides. Such
information has become essential for understanding the
mechanisms of drug action, the utilization of clearance
pathways, the nature and extent of metabolism-induced
toxicity, the effect of race or gender differences on drug
efficacy and other important pharmacological questions.
The study of in vivo metabolism of therapeutic drugs has
traditionally required a chemical synthesis to incorporate a
radioisotope (usually14C) into the molecular structure at a
strategic location. If the target molecule is designed
correctly, it can undergo biotransformations while retaining
the radiolabel. After dosing the labeled drug and collecting
biological-fluid samples, a metabolite profile is obtained
using chromatographic separation and radiometric detection
of the labeled analytes. This approach is problematic for
therapeutic peptides in that extensive and rapid metabolism
involving amide bond cleavage makes the loss of the
radiolabel much more facile. This creates the dilemma of
obtaining very different metabolic profiles if different label
locations are used.
Several approaches have been developed in attempts to
minimize amide bond cleavage and incipient loss of
radiolabel for therapeutic peptides. These include: (i)
placing the radiolabel on an unnatural residue such as aD-
amino acid, where biological demand is low and there is
poor recognition by proteases; (ii) placing the label on the
amino acid residue with the poorest biological reincorpora-
tion; (iii) using multiple radiolabel sites to ensure the
retention of the radiophore in the molecular backbone. The
latter option can result in data that are convoluted and
difficult to interpret. In practice, dosing of a radiolabeled
drug is only a starting point for structural elucidation of
metabolites. Subsequent characterization by liquid chroma-
tography/tandem mass spectrometry (LC/MS/MS) experi-
ments is generally required.1 Even then, if the radiolabeled
moiety is lost from the peptide, there is a real possibility of
overlooking a major, biologically active peptide fragment.
Immunoaffinity chromatography (IAC) differs from
conventional chromatography in that, rather than differen-
tial solubility, it employs specific biological/biochemical
interactions associated with an antibody and antigen. This
high degree of selectivity becomes particularly important
with therapeutic drug analysis because the drug and
metabolites must be detected at low levels from among a
large number of potentially interfering species in a complex
plasma sample. In previous work, IAC has demonstrated
selective sample enrichment which has been shown to be
effective in extracting a peptide drug and metabolites from
plasma and other biological matrices at the detection level
required for such characterization.2–4 After the non-binding
components have been washed from the immunoaffinity
column, a denaturing solution can be used to elute the
antigens for further separation and characterization. A more
definitive characterization of the peptide metabolites can
then be achieved using either electrospray ionization (ESI)
or matrix-assisted laser desorption/ionization (MALDI)
mass spectrometry.
Several papers describing permutations of this combined
approach of immunoaffinity-liquid chromatography/elec-
trospray ionization mass spectrometry (IA-LC/ESI-MS)
have been published for quantitative determinations of
small organic molecules in biofluids.5–9A related approach,
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involving immunoaffinity extraction and matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry
(MALDI-TOFMS) has been used for rapid qualitative
screening of human blood for the presence of myotoxin
A,10 for the identification of metal binding proteins and
phospholipids,11 and for the screening of combinatorial
libraries.12 To our knowledge, the IAC/LC/MS approach
has not been applied as a tool for the study of therapeutic
peptide metabolism, either in on-line or off-line configura-
tions.
In the present work, we demonstrate the feasibility of
elucidating the metabolism of a therapeutic peptide by
combining IAC/capillary LC (mLC) coupled to ESI-MS for
on-line characterization of metabolites of a therapeutic
peptide in plasma. The immunoaffinity separation selec-
tively retains parent drug and any metabolic fragments that
have sufficiently conserved structures. These analytes can
then be separated by reversed-phase chromatography and
characterized mass spectrometrically. The ability to detect
the peptide in plasma at the desired levels and an attempt to
study the binding of the peptide to the antibody by
enzymatic digestion and mass spectrometry is demonstrated
herein. The drug used in this work, SNX-111, is a 25 amino
acid peptide (isotope-averaged molecular weight 2639.2,
Figure 1. Experimental setup of the immunoaffinity chromatography experiment.
Figure 2. Mass spectrum of SNX-111 from LC/MS experiment (3mL of 20 ng/mL on-column) in acetonitrile/ water/
TFA (50:50:0.1% v/v).
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monoisotopic molecular weight 2636.1) produced by solid-
phase synthesis. It is identical in chemical structure to
Conotoxin M VIIA, obtained from natural sources.13 It has
three internal disulfide bonds with the sequence as follows:
SNX-111 was chosen as a model analyte because of the
availability of the antibody to this compound and its
potential usage as a therapeutic drug.
EXPERIMENTAL
Materials
SNX-111 acetate was manufactured by Adria-SP, Inc
(Albuquerque, NM, USA). SNX-279 (MW 2653), a
methionineS-oxide metabolite of SNX-111, was obtained
from Neurex Corp. (Menlo Park, CA, USA). Trifluoroacetic
acid (TFA) was purchased from Sigma Chemical Co. (St.
Louis, MO, USA).HPLC grade acetonitrile, methanol and
Tris were obtained from Aldrich (Milwaukee, MN, USA).
C18 packing materials (5-mm silica particles, 300-A˚ pore
size) were from Vydac (Hesperia, CA, USA). Enzymes
were purchased from Promega Corporation (Madison, WI,
USA), including clostripain, endoproteinase Lys-C, mod-
ified trypsin and proteinase K. Rat plasma was produced
from EDTA anticoagulated blood collected from male
Wistar rats.
Antibody preparation
Preparation of SNX-111 bovine serum albumin.Bovine
serum albumin (BSA) was dissolved at 20 mg/mL in 14 mL
of distilled water in a 50-mL polypropylene flask. SNX-111,
at 10 mg/mL in 7 mL of water, was added (2:1 ratio; v/v)
and the mixture slowly stirred to mix at room temperature.
The conjugation was initiated by the drop-wise addition of
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, at 50 mg/
mL in 700mL of water. The reaction was gently stirred
overnight at 4°C, then centrifuged for 20 min in a Beckman
TJ6 centrifuge. The resulting precipitate was mixed with
50 mL of 0.01M ammonium bicarbonate buffer, pH 8.0.
One-mL aliquots (equivalent to 1 mg SNX-111 4 mg
BSA) were placed in 5-mL screw-cap vials, lyophilized to
dryness, and stored at 4°C until use. Spectrophotometric
analysis of the resulting conjugate indicated 4.5 moles of
SNX-111 per mole BSA.
Immunization of rabbits.Antibody was raised in rabbits at
Josman Laboratories (Napa, CA, USA). Four rabbits were
immunized with 1.25 mg of SNX-111-BSA immunogen in a
Freund’s complete adjuvant and normal saline (1:1; v/v)
emulsion with a biweekly schedule of injections over a
period of 3 months until adequate titers and sensitivities
were obtained. As previously reported,3 the sera from the
best responding rabbits (NXJ 149 and NXJ 150) were
harvested, and subsequently pooled to provide SNX-111
antiserum used in the RIA.
Rabbit anti-SNX-111 immunoglobulin G isolation.An
aliquot (15 mL) of the pooled polyclonal antiserum from
the rabbits was loaded on a Protein A-Sepharose column
(2 6 cm, glass) and the IgG eluted with 30 mL of glycine
buffer (0.1 M, pH 3.0). The eluted IgG was then dialyzed
against sodium bicarbonate buffer (0.1 M, pH 8.8) and
aliquotted for long term storage atÿ20°C.2
Preparation of Rabbit anti-SNX-111 IgG-CNBr-Sepharose-
4B Immunoaffinity gel.Isolated polyconal rabbit anti-SNX-
111 IgG (60 mg) in 15 mL of buffer A (0.1 M sodium
bicarbonate, pH 8.8, containing 0.5 M NaCl) was added to
6.0 g of CNBr treated Sepharose-4B gel in 100 mL of 0.001
M HCl, in a 25 250 mm glass column. The column ends
were plugged, and the column was then rotated gently, with
the gel reagents mixing for 2 h at 22°C. After draining the
solvent, 100 mL of buffer A containing 1.0 M 2-aminoetha-
nol was added to the remaining gel. After mixing for 2 h, the
column was run dry and the gel washed four times with the
sequence of 100 mL of buffer A, followed by 100 mL of
sodium acetate (0.1 M, pH 4.0) containing 0.5 M NaCl. The
gel was then equilibrated with phosphate buffered saline
(pH 7.40) and stored at 4°C until used to pack the
immunoaffinity HPLC column. Fresh [125I]-SNX-1112 of
known radioactivity was used to characterize the binding
capacity of the Sepharose-4B-IgG gel for SNX-111.
Column packing
The microbore immunoaffinity column and the reversed-
phase capillary columns were packed in-house using the
following procedure: for the reversed-phase capillary
column, C18 bonded phase silica particles were first
suspended in methanol in a stirring tank. The suspension
was then loaded into a high-pressure fitting attached at one
end to the column blank that was a 15-cm length of 250mm
i.d./350mm o.d. fused silica capillary (Polymicro Technol-
ogies, Phoenix, AZ, USA). The other end of the fitting was
attached to the outlet of a high-pressure syringe pump
(ISCO,mLC-500 micropump, Lincoln, NE, USA). The
packing pressure was increased to 5500 psi gradually as
the packing proceeded, then allowed to drop slowly
following completion of the packing process.
For the microbore immunoaffinity column, Sepharose-4B
gel (1 mL) immobilized SNX-111 antibody was sus-
pended in 50 mM of Tris buffer (pH = 7.5). PEEK tubing
6 cm 1/16 in 1.0 mm i.d. (Alltech Associates, Inc.,
Deerfield, IL, USA) was substituted for the fused-silica
capillary used in the reversed-phase process. A lower
packing pressure (100–150 psi) was used to prevent
crushing of the Sepharose-4B particles. For some experi-
ments, a 2.1 mm 10 cm empty PEEK column (Upchurch
Scientific, Oak Harbor, WA, USA) was packed with
immunoaffinity gel by a similar process. A 2.0 25 cm
reversed-phase C18 column (Vydac, Hesperia, CA, USA)
was used in tandem with this larger bore immunoaffinity
column. For these larger scale columns, a flow rate of
200mL/min and injection volumes of 10mL were used.
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Chromatographic system
The column switching and HPLC system consisted of a Star
9012 solvent delivery system (Varian Associates, Inc.,
Walnut Creek, CA, USA), two Valco Model C6W valves
(Valco Instruments Co. Inc., Houston, TX, USA) equipped
with a 10-mL external sample loop, and a Star 9050 (Varian)
variable wavelength UV detector. For some experiments, a
series 200 chromatograph (Perkin-Elmer, Norwalk, CT,
USA) equipped with dual high-pressure mixing binary
gradient pumps and an autosampler, and a 10-port
electrically activated switching valve (Valco Instruments)
was used. To minimize the dead-volume during the UV
monitoring process, the original 4.5-mL flow cell in the UV
detector was replaced with a 60-nL microcapillary flow cell.
A valve located immediately before the injection point was
used to split (40:1) the mobile phase flow, to reduce the
normal flow rate from 200 to 5mL/min for the capillary
column. The analytical column that followed the immu-
noaffinity column was a fused-silica capillary (0.25 mm
i.d. 150 mm) packed with a 5-mm Vydac C18 218 TP
stationary phase. The end of the column was connected
directly to a piece of 75-mm i.d. fused-silica capillary
terminated at the electrospray needle assembly. The use of a
packed capillary column has several advantages, including
improved mass sensitivity and easy coupling to a mass
spectrometer. This microbore immunoaffinity column also
increased the sensitivity and could be operated at a low flow
rate (5mL/min) compatible with the capillary HPLC
analytical column under electrospray conditions. Thus, no
post-column flow splitting or trapping column was needed.
Aliquots (4mL) of rat plasma or aqueous buffer sample
containing SNX-111 and/or other analytes of interest were
directly injected onto the immunoaffinity column. Isocratic
chromatographic conditions were used for both the analyte
loading and elution processes. The immunoaffinity loading
buffer was 50 mM Tris at near-physiological pH (pH = 7.5).
Unretained and weakly bound sample components were
washed from the immunoaffinity column and passed to
waste. All analytes (antigens), as recognized by the
immunoaffinity process, were retained. A step-wise solvent
switch (to 10:90 acetonitrile : water, with 0.1% TFA)
reversibly denatured the antibodies, thus allowing release
of analytes from the immunoaffinity column, concentrating
them at the head of the reversed-phase (RP) column. The
pump was switched to the capillary analytical column and a
higher percentage of acetonitrile eluent solution (30:70
acetonitrile : water containing 0.1% TFA) was used to elute
the bound analytes from the RP column and into the mass
spectrometer. At the end of each run, the immunoaffinity
column was re-equilibrated with 50 mM Tris buffer, prior to
introduction of the next sample. Eluents leaving the
columns were also monitored by a UV detector at 214 nm.
The detector was digitized through a 16-bit analog-to-digital
converter board embedded in a 486 PC compatible
computer. Figure 1 shows the experimental setup of the
column switching arrangement used.
Mass spectrometry
An ion trap storage/reflectron time-of-flight (IT/reTOF)
mass spectrometer, which consists of a differentially
pumped reflectron time-of-flight mass spectrometer (model
D850) interfaced to a quadrupole ion trap storage device
(Model C-1251, R. M. Jordan Co., Grass Valley, CA, USA),
was used for detection. The details of this instrument have
been described in previous publications.14 For some
experiments involving the isolation of compound andS-
oxide from rat plasma, an API-365 triple quadrupole mass
spectrometer (PE-SCIEX, Toronto, CA, USA) equipped
with a Turbo ionspray interface was used.
RESULTS AND DISCUSSION
Characterization of immunoaffinity column capacity
Using fresh [125I] SNX-111 it was found that the swollen
Sepharose-4B-IgG gel bound approximately 3mg of SNX-
111 per mL. The microbore IA column used in these
experiments was 6 cm 1 mm i.d., with a corresponding
volume of 0.047 mL. This calculates to a total binding
capacity of 0.14mg of SNX-111 equivalent for the column.
A larger IA column, used in some of the narrow-bore
(2.1 mm) work, had column volume and binding capacity of
0.35 mL and 1000mg equivalents, respectively.
Table 1. Enzymatic digest fragments retained by the immunoaffinity column
Lys-C digest Trypsin digest
Mass Mass Mass Mass
Fragment calc. seen Fragment calc. seen
Breaking CK 249.3 not obs. CK 249.3 Not obs.
the GK 203.2 204.1 GK 203.2 204.1
disulfide GAK 274.3 274.9 GAK 274.3 274.9
bond CSRLMYDC 990.2 989.7 CSR 364.4 365.3
CTGSCRSGK 898.0 897.2 SGK 290.3 Not obs.
C 121.1 122.0 LMYDC 643.8 Not obs.
CTGSCR 625.7 Not obs.
C 121.1 121.7
Without GK 203.2 204.1 GK 203.2 204.1
breaking GAK 274.3 275.0 GAK 274.3 275.0
the CTGSCRSGKC 2204.6 2235.0 SGK 290.3 Not obs.
disulfide CTGSCR 1203.4 1204.5
bond CK CSRLMYDC
CK CSR
LMYDC-C 746.9 Not obs.
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Mass spectrometry
Proteins and peptides are known to be multiply charged in
electrospray ionization mass spectrometry. The profiles of
charge state distributions are a function of solution pH,15
solvent composition,16 instrumental conditions,17 tempera-
ture,18 presence of detergent,19 the number of basic or acidic
sites,20 the solution ionic strength21 and protein conforma-
tion.22 A strong correlation has been observed between the
number of basic amino acid residues present in the peptides
and proteins and the distribution of charge states observed in
its positive ESI spectrum. Figure 2 shows a mass spectrum
of a sample of SNX-111, obtained using LC/MS with
electrospray ionization on the IT/reTOF mass spectrometer.
This resulted in multiply charged [M 4H]4 and
[M  5H]5 ions atm/z660.4 and 528.4, respectively. No
mass spectrometry fragment ions were observed under these
conditions, possibly because of the high degree of disulfide
cross-linking in the molecule, which makes fragmentation
difficult. Signal-to-noise (S/N) ratio for this experiment was
limited by the performance of the instrumentation, with the
S/N for the m/z 528 ion only marginally distinguishable
from baseline noise.
Characterization of immunoaffinity antigen recognition
To gain understanding of antigen recognition and binding,
several enzymatic digestions using trypsin, endoproteinase
Lys-C and proteinase K were performed on the peptide in
clean solution. The digestions were performed before and
after the dithiothreitol reduction of disulfide cross linkages
(3 present). Structural assignments of all digest fragments
Figure 3. UV chromatogram and total ion chromatogram of plasma mixture after separation by a capillary reversed-
phase column without the use of the immunoaffinity column in the setup of Fig. 1.
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were based simply on mass-to-charge ratios (m/z) obtained
by LC/MS rather than sequence characterization by tandem
mass spectrometry. The results show that the disulfide bond
is critical in terms of forming the antigen/antibody-binding
site. Otherwise, due to the multiple cleavages (5 Arg and
Lys residues in SNX-111) in the trypsin digest, no specific
binding was clearly demonstrated and most of the fragments
were not retained. Proteinase K exhibits very low cleavage
specificity as it cleaves at the carboxylic sides of aromatic,
hydrophobic and aliphatic amino acids. The fragments from
these digests were too small to show affinity to the antigen.
In the Lys-C digest without disulfide bond reduction, a large
fragment with [M 2H]2 and [M 3H]3 ions at m/z
1117.5 and 745.2 was retained along with the original SNX-
111 on the immunoaffinity column, while small fragments
were unretained. It appears as if this fragment is an adduct
form of the large fragment atm/z2204.6 (Table 1). In the
trypsin digest, a fragment withm/z1204.5 was also retained
on the immunoaffinity column. The structure of this
fragment is very similar to that of the fragment observed
in the Lys-C digest atm/z1117.5 and 745.2, in that both
contain KC-CTGSCR-CSR. It is reasonable to suppose that
the above fragment contains the epitope or antibody binding
site. As long as this binding site is conserved within the
peptide fragment, it will be bound and retained by the
immunoaffinity column.
Figure 3 shows the UV and total ion chromatograms
(TICs) obtained by injecting 4mL of rat plasma sample
(with a spiked concentration of 0.2mg/mL SNX-111) onto
the capillary reversed-phase column system, followed by
mass detection without the benefit of sample cleanup from
the immunoaffinity column. The peak for SNX-111
(retention time of approximately 8 min) could barely be
distinguished from the endogenous components of the
Figure 4. UV detection and the total ion chromatogram of the bound analytes from the plasma sample following
elution of the sample from the immunoaffinity column.
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plasma sample. When an aliquot (4mL) of spiked rat plasma
was injected onto the immunoaffinity column, the un-
retained and weakly bound plasma components eluted from
the 0.25 150 mm C18 capillary column and were
subjected directly to mass detection using ESI. By
comparing the results of the plasma mixture separated only
by the capillary LC/MS without the immunoaffinity column
(Fig. 3) and that with the IAC (not shown), little difference
was observed, indicating that most components in the
plasma were not retained on the immunoaffinity column.
The pump was then switched to the capillary analytical
column and a higher percentage (30%) of acetonitrile was
used to elute the immunoaffinity bound analytes. Figure 4
shows the UV and TICs of the analytes after immunoaffinity
Figure 5. ESI mass spectrum of the bound analytes eluted from the immunoaffinity column, exclusively SNX-111.
Figure 6. Reconstructed ion chromatogram of SNX-111 to go with Fig. 5.
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extraction and reversed-phase separation, where, in each
case, a peak for SNX-111 is clearly observed at 8 min. The
corresponding mass spectrum of the SNX-111 peak is
shown in Fig. 5. We attribute differences between this
spectrum, in which the M 3 ion dominated, and that
shown in Fig. 2, where the M 4 ion is dominant to solvent
composition differences between the immunoaffinity/LC/
MS experiment and an LC/MS experiment where no
immunoaffinity experiment was used (Figure 2). A
reconstructed ion chromatogram is shown in Fig. 6.
Because of quantitation issues at this point in the study,
the remainder of the mass spectrometry work was conducted
using a Sciex API 365 triple quadrupole mass spectrometer.
Figure 7(a) shows a TIC for a rat plasma sample from a
subject animal dosed intravenously with SNX-111. The
sample (2mL) was diluted with mobile-phase buffer and
injected onto the 2.1 100 mm immunoaffinity column,
with subsequent separation on a 2.1 250 mm reversed-
phase column. Much of the information content in this
chromatogram is obscured by separation artifacts or noise.
The peak at 8 min represents parent drug at a concentration
of approximately 100 ng/mL (40 nM), based on a previous
quantitative determination of SNX-111 in this sample. The
selected ion chromatogram (m/z= 880.0, 3 ion) shown in
Fig. 7(b) demonstrates the high selectivity for SNX-111
when a selected ion channel is monitored. Good signal-to-
noise (S/N 25) was obtained for the analyte peak (8 min).
An additional peak at 2.8 min, not discernible in Fig. 7(a),
was shown to have a mass spectrum withm/zpeaks at 885.3
and 664.3. These mass spectral features suggest the identity
of this component to be the methionineS-oxide metabolite.
Subsequent injection of a solution of the pure compound
into this system confirmed this assertion. A selected ion
chromatogram (m/z885.3), shown in Fig. 7(c), demonstrates
a readily detectable peak with a S/N ratio of 4. A
quantitative determination of SNX-111 in this sample
suggests that the level ofS-oxide is approximately 5 ng/mL
(2 nM). No other significant chromatographic peaks were
apparent in the chromatogram, suggesting that if other
metabolites were present in the sample then they were at
levels below their detection limits. From the characteriza-
tion of the various peptide digests shown above, it is
expected that metabolites above several hundred Da would
be retained and detected if present at concentration levels
above the instrumental detection limits.
These results demonstrate the utility of on-line immu-
noaffinity liquid chromatography mass spectrometry for
extracting and characterizing a parent drug and a structu-
rally similar metabolite in a biological fluid. The on-line
immunoaffinity extraction performs analyte isolation from
the matrix through immunologically programmed molecu-
lar recognition. Selection between related analytes is
created through a simple reversed-phase gradient separa-
tion. Analyte identification is provided by single mass-
analyzer mass spectrometry. In this way, it is possible to use
this approach to gather metabolic information without the
need for radiolabeled drug compound.
As expected, samples extracted using an IAC column
indicate that greatly superior selectivity is obtained with
IAC in comparison with samples directly onto a reverse-
phase column and the SNX-111 can be readily detected in
complicated matrices such as blood plasma. SNX-111 can
readily be detected to a limit of 10 ng/mL or a correspond-
ing limit of 4 fmol/mL using selected ion recording at
880.0 Da on the triple quadrupole mass spectrometer. We
expect that results from an ion trap mass spectrometer
would be similar to or better than the results obtained from
these triple quadrupole experiments.
CONCLUSIONS
It appears feasible to use a combination of immobilized
polyclonal antibodies (immunoaffinity chromatography) in
tandem with capillary liquid chromatography and time-of-
flight mass spectrometry to qualitatively elucidate the
metabolism of therapeutic peptides. Plasma samples can
be introduced directly onto the immunoaffinity column
without prior preparation. The peptide and structurally
similar metabolites can be retained by the IA step while
endogenous sample components are washed to waste. The
analytes are then eluted from the immunoaffinity column
and characterized directly by on-line liquid chromatogra-
phy/mass spectrometry. One potential advantage of such a
system include the possibility of performing automated
sample extraction and trace enrichment with on-line mass
spectral identification of peptide drugs directly from plasma
or other biological fluids. A second possible advantage is
the ability to elucidate peptide metabolism without the
necessity for radiolabels. Although unlikely to replace this
well-established approach, the immunoaffinity experiments
Figure 7. Ion chromatograms from immunoaffinity-reversed-phase
chromatography/mass spectrometry for a rat plasma sample 1 h after
intravenous dosing of SNX-111. (a) total ion chromatogram, (b)
selected ion chromatogram (m/z 880.0), and (c) selected ion
chromatogram (m/z885.3).
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could complement the use of radiolabeled compounds in
situations where a radiolabeled site is lost from the peptide.
We anticipate that this approach could be exploited more
fully in the future.
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